Heartbeam Inc Stock Price, News & Analysis

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology firm, will present at the LD Micro Main Event XV Conference in Los Angeles from October 25-27, 2022. CEO Branislav Vajdic, PhD, will lead in-person meetings and a presentation on October 25 at 4:30 pm PT in TRACK 3. The conference highlights HeartBeam's unique 3D-vector ECG technology for heart attack detection. The presentation can be streamed live or viewed later on their investor relations site. More details on registration and the conference can be found online.

HeartBeam, Inc. (NASDAQ: BEAT) announced the appointment of Dr. Peter J. Fitzgerald as Chief Medical Officer. Dr. Fitzgerald, a leader in interventional cardiology, brings extensive clinical experience and expertise in developing industry collaborations. He aims to enhance clinical strategies and partnerships for advancing HeartBeam's novel diagnostic tools, including the 3D-vector ECG platform designed for heart attack detection. HeartBeam's innovative products, AIMI™ and AIMIGo™, are currently pending FDA clearance, with potential to significantly improve patient outcomes.

HeartBeam, Inc. (NASDAQ: BEAT) has announced the expansion of its product portfolio to address the multibillion-dollar atrial arrhythmia detection market. New developments include the HeartBeam AIMIGo™ 3L device, designed to record 3D cardiac activity and facilitate clinician reviews with a planned FDA submission in Q4 2022. Future versions will add smartwatch connectivity and enhanced atrial fibrillation detection. The company is also ensuring component procurement for device production to mitigate supply chain issues, pushing towards comprehensive cardiac care anytime, anywhere.

HeartBeam, Inc. (NASDAQ: BEAT) will present at the Dawson James Small Cap Growth Conference on October 12, 2022 in Jupiter, FL, and at The ThinkEquity Conference on October 26, 2022 in New York City. The company's leadership team, including CEO Branislav Vajdic, will conduct presentations and one-on-one meetings. HeartBeam has developed a unique 3D-vector ECG platform for heart attack detection, enhancing patient care through rapid assessment of heart symptoms.

HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, enabling a synthesized 12-lead ECG outside medical settings. This innovation allows patients to send heart signal data directly to physicians, enhancing heart attack detection. With around 18 million individuals in the US at risk for heart attacks, the technology addresses a significant healthcare need. HeartBeam's AIMIGo is the only wallet-sized 12-lead ECG solution, aiming to reduce emergency visits and expedite care while improving patient quality of life.

HeartBeam, Inc. (NASDAQ: BEAT) announced a virtual roadshow webinar set for September 20, 2022, at 4:30 p.m. ET. The company released a video showcasing its AIMIGo technology, a credit card-sized ECG device for remote heart attack detection, which is expected to receive FDA clearance by year-end. This technology aims to enhance heart attack detection capabilities outside medical settings, expediting treatment and reducing healthcare costs. Key executives will discuss recent announcements and milestones during the webinar.

HeartBeam, Inc. (NASDAQ: BEAT) has received a patent for its innovative 12-lead ECG patch monitor, which allows for the detection of acute coronary syndrome and cardiac arrhythmia outside medical settings. This technology enhances traditional ECG diagnostics, contributing to a projected global market of $4.8B by 2030. The new patent complements existing patents, bolstering HeartBeam's intellectual property portfolio and offering potential advancements in cardiac care diagnostics.

HeartBeam, Inc. (NASDAQ: BEAT) has announced a virtual roadshow webinar on September 20, 2022, at 4:30 p.m. ET. During this event, a new video showcasing the HeartBeam AIMIGo technology for heart attack detection will be unveiled. While the AIMI and AIMIGo technologies are pending FDA clearance, they aim to enhance heart attack detection outside of medical settings. The webinar will feature CEO Branislav Vajdic and other executives discussing the company’s milestones and 510(k) application progress. Access the webinar via the provided link.

HeartBeam, Inc. (NASDAQ: BEAT) has submitted a 510(k) application to the US FDA for its HeartBeam AIMI™ technology, aimed at improving heart attack diagnosis. This step is crucial for the company's commercialization efforts within a $500 million market. With over 18 million individuals affected by coronary artery disease in the US, and heart attacks occurring every 40 seconds, the technology aims to enhance the diagnostic process in emergency departments. CEO Branislav Vajdic expressed optimism regarding FDA clearance and anticipated a full commercial roll-out in Q1 2023.